An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example
Open accessAbstract
Decision models can combine information from different sources to simulate the long-term consequences of alternative strategies in the presence of uncertainty. A cohort state-transition model (cSTM) is a decision model commonly used in medical decision making to simulate the transitions of a hypothetical cohort among various health states over time. This tutorial focuses on time-independent cSTM, in which transition probabilities among health states remain constant over time. We implement time-independent cSTM in R, an open-source mathematical and statistical programming language. We illustrate time-independent cSTMs using a previously published decision model, calculate costs and effectiveness outcomes, and conduct a cost-effectiveness analysis of multiple strategies, including a probabilistic sensitivity analysis. We provide open-source code in R to facilitate wider adoption. In a second, more advanced tutorial, we illustrate time-dependent cSTMs.
AI snapshot
Written from the paper’s full text.
TL;DR
This tutorial conceptualizes time-independent cohort state-transition models (cSTMs) and demonstrates their implementation in base R using a 4-state Sick-Sicker cost-effectiveness analysis example. It provides open-source code and illustrates CEA, probabilistic sensitivity analysis, and related outputs such as ICERs, CEACs, CEAFs, and expected loss curves.
Key findings
- The tutorial implements time-independent cSTMs in R without requiring a specialized cSTM package, using a previously published 4-state Sick-Sicker model to compare standard of care (SoC), strategy A, strategy B, and strategy AB.
- In the base-case CEA, SoC is least costly and effective; strategy B yields an expected incremental benefit of 1.473 QALYs per individual for an additional expected cost of $107,521, with an ICER of $72,988/QALY; strategy AB has an ICER of $125,764/QALY; strategy A is dominated.
- In the PSA with 1,000 parameter sets, SoC has the highest probability of being cost-effective and highest expected NMB at WTP thresholds below $80,000/QALY; strategy B is optimal between $80,000 and $120,000/QALY; strategy AB is optimal at WTP thresholds greater than or equal to $120,000/QALY.
- The tutorial also demonstrates within-cycle correction using Simpson’s 1/3rd rule and discounting of costs and QALYs at an annual rate of 3%.
Methods
- Tutorial design: step-by-step mathematical conceptualization and R implementation of time-independent cSTMs, with code in a GitHub repository; the case study is a previously published 4-state Sick-Sicker model for a CEA of four strategies (SoC, A, B, AB).
- Cohort and model: hypothetical cohort of 25-year-olds starting in the “Healthy” state, simulated until maximum age 100 years using annual cycles (75 one-year cycles); transition rates are converted to probabilities, and costs and QALYs are discounted at 3% annually with within-cycle correction.
- Analysis: base-case cost-effectiveness analysis with ICERs, plus probabilistic sensitivity analysis sampling 1,000 parameter sets from distributions (gamma for transition rates, lognormal for hazard ratios, beta for utility weights), producing cost-effectiveness scatter plots, CEACs, CEAFs, and expected loss curves.
Limitations
- The paper states that the example assumes all parameters are known or that their uncertainty distributions are known; real-world cSTMs require thorough evidence synthesis, and the PSA assumes all parameters are independent, whereas parameters could be correlated or rank ordered.
- The paper states that cSTMs are recommended when the number of states is “not too large,” that unit testing is beyond the tutorial’s scope, and that the tutorial focuses on time-independent cSTMs only, with time-dependent models covered in an advanced tutorial.
- Evident from the text: the case study is a hypothetical disease and illustrative model, not a real-world clinical or policy evaluation, and the reported results are specific to the Sick-Sicker example and its assumed inputs.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
3 of 9 cited sources checked · 2 supported · 0 flagged · accuracy not yet measured
- Study design and conductcitation
The probabilistic sensitivity analysis randomly drew parameter sets from distributions that reflect the current uncertainty in model parameter estimates.
“To quantify the effect of model parameter uncertainty on cost-effectiveness outcomes, we conducted a PSA by randomly drawing K parameter sets (n_sim) from distributions that reflect the current uncertainty in model parameter estimates.26”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [26] Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Medical Decision Making. 2012 Sep; 32(5): 722– 32. 22990087 source
- Findingreasoning
In the Sick-Sicker model, because the Dead state is absorbing, the proportion of the cohort in that state increases over time.
“Given that the D state is absorbing, the proportion in this state increases over time.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: The cohort is homogeneous within each health state.
- The authors state this as an assumption: Individuals in the cohort residing in a particular health state have the same characteristics and are indistinguishable from one another.
- The authors state this as an assumption: In a cSTM, transition probabilities depend only on the current health state in a given cycle and not on the history of past transitions or time spent in a given state (the Markovian assumption).
- The authors state this as an assumption: The rate of becoming sick is constant over the year, implying that the time until a healthy person becomes sick is exponentially distributed.
- The authors state this as an assumption: All transitions to non-death states are conditional on surviving to the end of a cycle.
- The authors state this as an assumption: It is not possible to distinguish between Sick and Sicker patients, so individuals in both disease states receive the treatment under the treatment strategies.
- Findingown data
Strategy AB has an ICER of $125,764 per QALY.
“SoC is the least costly and effective strategy, followed by Strategy B producing an expected incremental benefit of 1.473 QALYs per individual for an additional expected cost of $107,521 with an ICER of $72,988/QALY followed by Strategy AB with an ICER $125,764/QALY.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: All parameters of the example model are known, or at least the characterization of their uncertainty (their distributions) is known.
- Findingown data
In the probabilistic sensitivity analysis of the time-independent model, strategy AB has the highest expected costs and QALYs.
“The CE scatter plot for CEA using the time-independent model shows that strategy AB has the highest expected costs and QALYs.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: All model parameters are independent of each other in the probabilistic sensitivity analysis.
- Findingown data
Strategies SoC, B and AB form the cost-effectiveness efficient frontier.
“Strategies SoC, B and AB form the cost-effectiveness efficient frontier (Figure 3).”
Quote in the paperSubstantial claim- The authors state this as an assumption: All parameters of the example model are known, or at least the characterization of their uncertainty (their distributions) is known.
- Findingown data
Strategy A is a dominated strategy.
“Strategy A is a dominated strategy (Table 5).”
- Also stated in: § Probabilistic sensitivity analysis · boosted
“Strategy A is a strongly dominated strategy.”
Quote in the paperSubstantial claim- The authors state this as an assumption: All parameters of the example model are known, or at least the characterization of their uncertainty (their distributions) is known.
- Also stated in: § Probabilistic sensitivity analysis · boosted
- Interpretationreasoning
Using specialized cSTM packages can be challenging if the desired cSTM does not fit within their pre-defined structure.
“However, these packages are necessarily stylized and require users to specify the structure and inputs of their cSTM in a particular way potentially without fully understanding how cSTMs work. Using these packages can be challenging if the desired cSTM does not fit within this structure.”
Quote in the paperSubstantial claim - Premisecitation
Within-cycle correction is an approach to reducing the biases introduced by discretization in discrete-time cSTMs.
“Another approach is to use within-cycle corrections (WCC).2,22”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [2] Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Medical Decision Making [Internet]. 2012; 32(5): 690– 700. Available from: http://mdm.sagepub.com/cgi/doi/10.1177/0272989X12455463 22990084 source
- cites [22] Hunink MGGM Weinstein MC, Wittenberg E, Drummond MF, Pliskin JS Wong JB, Decision Making in Health and Medicine [Internet]. 2nd ed. Cambridge: Cambridge University Press; 2014. Available from: http://ebooks.cambridge.org/ref/id/CBO9781139506779 source
- Premisecitation
The discretization of continuous-time dynamics in a discrete-time cSTM might introduce biases when estimating outcomes based on state occupancy.
“The discretization might introduce biases when estimating outcomes based on state occupancy.21”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [21] van Rosmalen J, Toy M, O’Mahony JF. A Mathematical Approach for Evaluating Markov Models in Continuous Time without Discrete-Event Simulation. Medical Decision Making [Internet]. 2013 May; 33(6): 767– 79. Available from: http://mdm.sagepub.com/cgi/doi/10.1177/0272989X13487947 23715464 source
- Classified as probably not a substantial claim. 14
- May combine two claims. 15
- The quote only partly states this claim. 1
Classified as probably not a substantial claim. May combine two claims.
PremisecitationThe markovchain package simulates time-independent and time-dependent Markov chains but is not designed to conduct economic evaluations.
“The markovchain package simulates time-independent, and time-dependent Markov chains but is not designed to conduct economic evaluations.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [10] Spedicato GA. Discrete Time Markov Chains with R. The R Journal [Internet]. 2017; 9(2): 84– 104. Available from: https://journal.r-project.org/archive/2017/RJ-2017-036/RJ-2017-036.pdf source
The Introduction describes simulating trajectories from a discrete-time Markov chain, and the Non homogeneous Markov chains section describes handling time-dependent chains; its example says rmarkovchain also works on those chains. The Additional information section says the package was designed for common operations on discrete-time Markov chains, but our copy does not explicitly establish that it is not designed to conduct economic evaluations. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing). May combine two claims.
PremisecitationModel parameters could be correlated or have a rank order, so statistical methods that simulate these correlations or rank order might be needed.
“However, parameters could be correlated or have a rank order, and appropriate statistical methods that simulate these correlations or rank order might be needed.32”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [32] Goldhaber-Fiebert JD, Jalal HJ. Some Health States Are Better Than Others: Using Health State Rank Order to Improve Probabilistic Analyses. Medical Decision Making [Internet]. 2015; 36(8): 927– 40. Available from: http://mdm.sagepub.com/cgi/doi/10.1177/0272989X15605091 26377369 PMC4794424 source
May combine two claims.
Findingown dataAt willingness-to-pay thresholds greater than or equal to $120,000 per QALY gained, strategy AB has the highest probability of being cost-effective and the highest expected net monetary benefit.
“This switches to strategy B for WTP thresholds between $80,000 and $120,000 per QALY gained and to strategy AB for WTP thresholds greater than or equal to $120,000 per QALY gained.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: All model parameters are independent of each other in the probabilistic sensitivity analysis.
May combine two claims.
Findingown dataAt willingness-to-pay thresholds below $80,000 per QALY gained, strategy SoC has both the highest probability of being cost-effective and the highest expected net monetary benefit.
“At WTP thresholds less than $80,000 per QALY gained, strategy SoC has both the highest probability of being cost-effective and the highest expected NMB.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: All model parameters are independent of each other in the probabilistic sensitivity analysis.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone givenIn the Sick-Sicker model, the whole cohort starts in the Healthy state and transitions to the rest of the states over time.
“The whole cohort starts in the H state and transitions to the rest of the states over time.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: The cohort is homogeneous within each health state.
- The authors state this as an assumption: Individuals in the cohort residing in a particular health state have the same characteristics and are indistinguishable from one another.
- The authors state this as an assumption: In a cSTM, transition probabilities depend only on the current health state in a given cycle and not on the history of past transitions or time spent in a given state (the Markovian assumption).
- The authors state this as an assumption: The rate of becoming sick is constant over the year, implying that the time until a healthy person becomes sick is exponentially distributed.
- The authors state this as an assumption: All transitions to non-death states are conditional on surviving to the end of a cycle.
- The authors state this as an assumption: It is not possible to distinguish between Sick and Sicker patients, so individuals in both disease states receive the treatment under the treatment strategies.
May combine two claims.
Findingown dataStrategy B produces an expected incremental benefit of 1.473 QALYs per individual for an additional expected cost of $107,521, giving an ICER of $72,988 per QALY.
“SoC is the least costly and effective strategy, followed by Strategy B producing an expected incremental benefit of 1.473 QALYs per individual for an additional expected cost of $107,521 with an ICER of $72,988/QALY followed by Strategy AB with an ICER $125,764/QALY.”
Quote in the paperSubstantial claim- The authors state this as an assumption: All parameters of the example model are known, or at least the characterization of their uncertainty (their distributions) is known.
May combine two claims. The quote only partly states this claim.
Findingown dataAmong the four strategies in the base-case analysis, standard of care (SoC) is the least costly and least effective strategy.
“SoC is the least costly and effective strategy, followed by Strategy B producing an expected incremental benefit of 1.473 QALYs per individual for an additional expected cost of $107,521 with an ICER of $72,988/QALY followed by Strategy AB with an ICER $125,764/QALY.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: All parameters of the example model are known, or at least the characterization of their uncertainty (their distributions) is known.
May combine two claims.
Findingown dataAt willingness-to-pay thresholds between $80,000 and $120,000 per QALY gained, strategy B has the highest probability of being cost-effective and the highest expected net monetary benefit.
“This switches to strategy B for WTP thresholds between $80,000 and $120,000 per QALY gained and to strategy AB for WTP thresholds greater than or equal to $120,000 per QALY gained.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: All model parameters are independent of each other in the probabilistic sensitivity analysis.
May combine two claims.
Findingown dataIn the probabilistic sensitivity analysis, standard of care has the lowest expected cost and QALYs.
“Standard of care has the lowest expected cost and QALYs.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: All model parameters are independent of each other in the probabilistic sensitivity analysis.
May combine two claims.
Findingown dataIn the probabilistic sensitivity analysis, strategy B is more effective and less costly than strategy A.
“Strategy B is more effective and least costly than Strategy A.”
Quote in the paperSubstantial claim- The authors state this as an assumption: All model parameters are independent of each other in the probabilistic sensitivity analysis.
May combine two claims.
PremisereasoningShortening the cycle length reduces the biases from discretization but requires simulating the model for a larger number of cycles, which can be computationally burdensome.
“One approach to reducing these biases is to shorten the cycle length, requiring simulating the model for a larger number of cycles, which can be computationally burdensome.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationcSTMs can also be implemented in R via discrete-time difference equations or continuous-time differential equations, in addition to a discrete-time transition matrix.
“However, cSTM can also be implemented via (discrete-time) difference equations or (continuous-time) differential equations in R.35,36”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [35] Grimmett G, Welsh D. Markov Chains. In: Probability: An introduction [Internet]. 2nd ed. Oxford University Press; 2014. p. 203– 3. Available from: www.statslab.cam.ac.uk/{~}grg/teaching/chapter12.pdf
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [36] Axler S, Gehring FW, Ribet KA. Difference Equations. In New York, NY: Springer; 2005. Available from: http://link.springer.com/10.1007/0-387-27645-9 source
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Interpretationnone givenReasonably complex cSTMs can be built in R as long as the computer's RAM can store the size of the transition probability matrix and the outputs of interest.
“It is possible to build reasonably complex cSTMs in R as long as the computer’s RAM can store the size of the transition probability matrix and outputs of interest.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAll transition probabilities in a transition probability matrix should have values between 0 and 1.
“The elements of P are the transition probabilities of moving from state i to state j, p[i,j], where {i, j} = 1, …, nS and all should have values between 0 and 1.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
InterpretationreasoningFor time-independent cSTMs, the capacity of current RAM in personal computers should generally not be a problem.
“For time-independent cSTMs, in general, this should not be a problem with the capacity of current RAM in personal computers.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
InterpretationreasoningThe cohort trace matrix M stores the output of the cSTM and can be used to compute epidemiological and economic outcomes such as life expectancy, prevalence, cumulative resource use, and costs.
“Thus, M stores the output of the cSTM, which could be used to compute various epidemiological, and economic outcomes, such as life expectancy, prevalence, cumulative resource use, and costs, etc.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductreasoningThe transition matrices created for the Sick-Sicker model were verified as valid by checking that each row sums to one and that each entry is between 0 and 1.
“Once all transition matrices are created, we verify they are valid by checking that each row sums to one and that each entry is between 0 and 1.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Interpretationnone givenThe general conceptualization of time-independent cSTMs presented in the tutorial should apply to other programming languages such as MATLAB, Python, C++, and Julia.
“Our general conceptualization should apply to other programming languages (e.g., MATLAB, Python, C++, and Julia).”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationCohort state-transition models (cSTMs) are usually computationally less demanding than individual-based state-transition models (iSTMs), providing the ability to conduct probabilistic sensitivity analysis (PSA) and value-of-information (VOI) analyses that otherwise might not be computationally feasible with iSTMs.
“cSTMs are usually computationally less demanding than individual-based state-transition models (iSTMs), providing the ability to conduct PSA and value-of-information (VOI) analyses that otherwise might not be computationally feasible with iSTMs.2”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [2] Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Medical Decision Making [Internet]. 2012; 32(5): 690– 700. Available from: http://mdm.sagepub.com/cgi/doi/10.1177/0272989X12455463 22990084 source
Probably not a substantial claim: may not pass S4 (based).
Premisenone givenHazard ratios apply to rates and not to probabilities.
“These calculations are required because hazard ratios only apply to rates and not to probabilities.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenSetting the seed of the pseudo-random number generator used in sampling parameter values ensures reproducibility of the PSA results.
“The function input seed sets the seed of the pseudo-random number generator used in sampling parameter values, which ensures reproducibility of the PSA results.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S4 (based).
Study design and conductnone givenFor a transition probability matrix to be correctly specified, each row of the matrix must sum to one.
“For P to be a correctly specified transition probability matrix, each row of the transition probability matrix must sum to one, ∑j=1nSp[i,j]=1 for all i = 1, …, nS.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based). May combine two claims.
Interpretationnone givenAlthough some implementation details presented in the tutorial are specific to the R programming language, much of the code structure shown would be similar in other programming languages.
“While some of the presented implementation details are specific to the R programming language, much of the code structure shown in this tutorial would be similar in other programming languages.”
Quote in the paperNot a substantial claim
The authors state this as an assumption.
The cohort is homogeneous within each health state.
“The cohort is assumed to be homogeneous within each health state.”
The authors state this as an assumption.
Individuals in the cohort residing in a particular health state have the same characteristics and are indistinguishable from one another.
“Individuals in the cohort residing in a particular health state are assumed to have the same characteristics and are indistinguishable from one another.”
The authors state this as an assumption.
In a cSTM, transition probabilities depend only on the current health state in a given cycle and not on the history of past transitions or time spent in a given state (the Markovian assumption).
“In a cSTM, the transition probabilities only depend on the current health state in a given cycle, meaning that the transition probabilities do not depend on the history of past transitions or time spent in a given state. This property is often referred to as the “Markovian assumption.””
The authors state this as an assumption.
The rate of becoming sick is constant over the year, implying that the time until a healthy person becomes sick is exponentially distributed.
“Equation (1) assumes that the rate of becoming sick is constant over the year, implying that the time until a healthy person becomes sick is exponentially distributed.”
The authors state this as an assumption.
All transitions to non-death states are conditional on surviving to the end of a cycle.
“We assume that all transitions to non-death states are conditional on surviving to the end of a cycle.”
The authors state this as an assumption.
It is not possible to distinguish between Sick and Sicker patients, so individuals in both disease states receive the treatment under the treatment strategies.
“We assume that it is not possible to distinguish between Sick and Sicker patients; therefore, individuals in both disease states receive the treatment under the treatment strategies.”
The authors state this as an assumption.
All parameters of the example model are known, or at least the characterization of their uncertainty (their distributions) is known.
“The parameterization of our example model assumes all parameters are known, or at least, the characterization of their uncertainty is known (i.e., we know their distributions).”
The authors state this as an assumption.
All model parameters are independent of each other in the probabilistic sensitivity analysis.
“Similarly, our PSA analysis simplifies reality where all model parameters are assumed to be independent of each other.”
Cites
Markov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419 · see citing works
Cost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552 · see citing works
Stinnett, A. A., & Mullahy, J. (1998) · Medical Decision Making · doi:10.1177/0272989x98018002s09 · Cited by 1,103 · see citing works
The Markov process in medical prognosis
Beck, J. R., & Pauker, S. G. (1983) · Medical Decision Making · doi:10.1177/0272989x8300300403 · Cited by 957 · cited 1× · see citing works
“15 This tutorial focuses on time-independent cSTM, meaning that model parameters, such as transition probabilities or reward (e.g., costs or utilities associated with being in a particular health state), do not vary with time.”
Briggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Medical Decision Making · doi:10.1177/0272989x12458348 · Cited by 887 · cited 2× · see citing works
“26 The distribution for all the parameters and their values are described in Table 2 and in more detail in the Supplementary Material.”
Robinson, R. (1993) · BMJ · doi:10.1136/bmj.307.6907.793 · Cited by 819 · see citing works
Decision Making in Health and Medicine: Integrating Evidence and Values
Hunink, M. G. M., Weinstein, M. C., Wittenberg, E., Drummond, M. F., Pliskin, J. S., Wong, J. B., & Glasziou, P. P. (2014) · doi:10.1017/cbo9781139506779 · Cited by 425 · cited 2× · see citing works
“2,22 In this tutorial, we use Simpson’s 1/3rd rule by multiplying the rewards (e.g., costs and effectiveness) by 1 / 3 in the first and last cycles, by 4 / 3 for the odd cycles, and by 2 / 3 for the even cycles.”
Self-citationBriggs, A. H., Goeree, R. A., Blackhouse, G., & O’Brien, B. J. (2002) · Medical Decision Making · doi:10.1177/0272989x0202200408 · Cited by 413 · cited 3× · see citing works
“29,33 In addition, modelers should appropriately specify all model parameters for the cycle length of the model.”
InfluentialAge-Specific Incidence and Prevalence: A Statistical Perspective
Keiding, N. (1991) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.2307/2983150 · Cited by 397 · see citing works
Carrier Screening for Cystic Fibrosis
Asch, D. A., Hershey, J. C., DeKay, M. L., Pauly, M. V., Patton, J. P., Jedrziewski, M. K., Frei, F. X., Giardine, R., Kant, J. A., & Mennuti, M. T. (1998) · Medical Decision Making · doi:10.1177/0272989x9801800209 · Cited by 375 · see citing works
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Medical Decision Making · doi:10.1177/0272989x12455463 · Cited by 348 · see citing works
Smith-Spangler, C. M., Juusola, J. L., Enns, E. A., Owens, D. K., & Garber, A. M. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-8-201004200-00212 · Cited by 244 · see citing works
Self-citationDetermining Transition Probabilities
Miller, D. K., & Homan, S. M. (1994) · Medical Decision Making · doi:10.1177/0272989x9401400107 · Cited by 197 · see citing works
Briggs, A. H., Ades, A. E., & Price, M. J. (2003) · Medical Decision Making · doi:10.1177/0272989x03255922 · Cited by 194 · see citing works
Neuts, M. F., Grimmett, G., & Welsh, D. J. A. (1988) · Journal of the American Statistical Association · doi:10.2307/2289326 · Cited by 189 · see citing works
Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial
Krijkamp, E., Alarid‐Escudero, F., Enns, E. A., Jalal, H. J., Hunink, M. G. M., & Pechlivanoglou, P. (2018) · Medical Decision Making · doi:10.1177/0272989x18754513 · Cited by 177 · see citing works
Self-citationDiscrete Time Markov Chains with R
Spedicato, G. (2017) · The R Journal · doi:10.32614/rj-2017-036 · Cited by 148 · see citing works
An Overview of R in Health Decision Sciences
Jalal, H. J., Pechlivanoglou, P., Krijkamp, E., Alarid‐Escudero, F., Enns, E. A., & Hunink, M. G. M. (2017) · Medical Decision Making · doi:10.1177/0272989x16686559 · Cited by 98 · see citing works
Self-citationModelling in economic evaluation
Kuntz, K. M., & Weinstein, M. C. (2001) · Economic Evaluation in Health Care · doi:10.1093/oso/9780192631770.003.0007 · Cited by 87 · see citing works
Cost-Effectiveness of Treatment of Diabetic Macular Edema
Pershing, S., Enns, E. A., Matesic, B., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2014) · Annals of Internal Medicine · doi:10.7326/m13-0768 · Cited by 74 · cited 1× · see citing works
“cSTMs have been used to evaluate screening and surveillance programs,(3,4) diagnostic procedures,(5) disease management programs,(6) interventions,(7) and policies.(8) In a recent review, we illustrated the increased use of R’s statistical programming framework in health decision sciences.”
Self-citationA Need for Change! A Coding Framework for Improving Transparency in Decision Modeling
Alarid‐Escudero, F., Krijkamp, E., Pechlivanoglou, P., et al. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00837-x · Cited by 66 · cited 1× · see citing works
“20 In this tutorial, we implemented a cSTM using a (discrete-time) transition matrix.”
Self-citationAssessing Uncertainty in Cost-Effectiveness Analyses
Parmigiani, G., Samsa, G., Ancukiewicz, M., et al. (1997) · Medical Decision Making · doi:10.1177/0272989x9701700404 · Cited by 50 · see citing works
Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer
Sathianathen, N. J., Konety, B. R., Alarid‐Escudero, F., Lawrentschuk, N., Bolton, D. M., & Kuntz, K. M. (2018) · European Urology · doi:10.1016/j.eururo.2018.10.055 · Cited by 47 · see citing works
Self-citationAlarid‐Escudero, F., Enns, E. A., Kuntz, K. M., et al. (2019) · Value in Health · doi:10.1016/j.jval.2019.02.008 · Cited by 47 · see citing works
Self-citationSuijkerbuijk, A. W. M., van Hoek, A. J., Koopsen, J., de Man, R. A., Mangen, M.-J., de Melker, H. E., Polder, J. J., de Wit, G. A., & Veldhuijzen, I. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207037 · Cited by 40 · see citing works
Measuring uncertainty in complex decision analysis models
Parmigiani, G. (2002) · Statistical Methods in Medical Research · doi:10.1191/0962280202sm307ra · Cited by 37 · see citing works
Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods
Elbasha, E. H., & Chhatwal, J. (2015) · Medical Decision Making · doi:10.1177/0272989x15585121 · Cited by 35 · cited 1× · see citing works
“23,24 We implement the WCC by generating a column vector wcc of size n T + 1 with values corresponding to the first, t = 0, and last cycle, t = n T , equal to 1 / 3, and the entries corresponding to the even and odd cycles with 2 / 3 and 4 / 3, respectively.”
Goldhaber-Fiebert, J. D., & Jalal, H. J. (2016) · Medical Decision Making · doi:10.1177/0272989x15605091 · Cited by 31 · cited 1× · see citing works
“32 We encourage modelers to use appropriate statistical methods to accurately synthesize and quantify model parameters’ uncertainty.”
Self-citationLü, S., Yu, Y., Fu, S., & Ren, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205827 · Cited by 31 · see citing works
Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers
Elbasha, E. H., & Chhatwal, J. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0337-0 · Cited by 30 · see citing works
Markov Models for Health Economic Evaluations: The R Package heemodPreprint
Filipović-Pierucci, A., Zarca, K., & Durand‐Zaleski, I. (2017) · arXiv (Cornell University) · doi:10.48550/arxiv.1702.03252 · Cited by 29 · see citing works
Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
Soares, M. O., & Castro, L. C. E. (2012) · PharmacoEconomics · doi:10.2165/11599380-000000000-00000 · Cited by 28 · cited 1× · see citing works
“…difference equations or (continuous-time) differential equations in R. 35,36 We refer readers interested in learning more on continuous-time cSTMs to previously published manuscripts 21,37–39 and a tutorial using R. 40 Finally, the variable names used in this paper reflect our coding style.”
Continuous-Time Semi-Markov Models in Health Economic Decision Making
Cao, Q., Buskens, E., Feenstra, T., et al. (2015) · Medical Decision Making · doi:10.1177/0272989x15593080 · Cited by 27 · cited 1× · see citing works
“…difference equations or (continuous-time) differential equations in R. 35,36 We refer readers interested in learning more on continuous-time cSTMs to previously published manuscripts 21,37–39 and a tutorial using R. 40 Finally, the variable names used in this paper reflect our coding style.”
Decision Models in Cost-Effectiveness Analysis
Kuntz, K. M., Russell, L. B., Owens, D. K., et al. (2016) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190492939.003.0005 · Cited by 26 · cited 2× · see citing works
“is_odd <- function(x) x %% 2 != 0 ## Vector with cycles v_cycles <- seq(1, n_cycles + 1) ## Generate 2/3 and 4/3 multipliers for even and odd entries, respectively v_wcc <- is_even(v_cycles)*(2/3) + is_odd(v_cycles)*(4/3) ## Substitute 1/3 in first and last entries v_wcc[1] <- v_wcc[n_cycles + 1] <- 1/3”
Identifying Best-Fitting Inputs in Health-Economic Model Calibration
Enns, E. A., Cipriano, L. E., Simons, C. T., et al. (2014) · Medical Decision Making · doi:10.1177/0272989x14528382 · Cited by 25 · see citing works
Self-citationElliott, W. J. (2011) · Yearbook of Cardiology · doi:10.1016/j.ycar.2011.01.053 · Cited by 25 · see citing works
Begun, A., Icks, A., Waldeyer, R., et al. (2012) · Medical Decision Making · doi:10.1177/0272989x12466731 · Cited by 24 · see citing works
A theoretical foundation for state-transition cohort models in health decision analysis
Iskandar, R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205543 · Cited by 24 · see citing works
van Rosmalen, J., Toy, M., & O’Mahony, J. F. (2013) · Medical Decision Making · doi:10.1177/0272989x13487947 · Cited by 22 · cited 2× · see citing works
“21 One approach to reducing these biases is to shorten the cycle length, requiring simulating the model for a larger number of cycles, which can be computationally burdensome.”
Frederix, G., van Hasselt, J. G. C., Severens, J. L., et al. (2013) · Medical Decision Making · doi:10.1177/0272989x13476763 · Cited by 14 · see citing works
dampack: Decision-Analytic Modeling Package
Alarid‐Escudero, F., Knowlton, G. S., Easterly, C., et al. (2021) · doi:10.32614/cran.package.dampack · Cited by 14 · see citing works
Self-citationCost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
Djatche, L. M., Varga, Š., & Lieberthal, R. D. (2018) · PharmacoEconomics - Open · doi:10.1007/s41669-018-0075-2 · Cited by 7 · see citing works
Alarid-Escudero, F., Krijkamp, E., Enns, E. A., Yang, A., Hunink, M. G. M., Pechlivanoglou, P., & Jalal, H. (2023) · Medical Decision Making · doi:10.1177/0272989x221121747 · Cited by 5 · see citing works
Self-citation(2005) · Undergraduate Texts in Mathematics · doi:10.1007/0-387-27645-9 · Cited by 4 · see citing works
Flagged first, then by citations
1 of the 45 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Rosmalen J van, 2013, Med Decis Making, 33
Cited by
Sorted by citations
Kunst, N., Siu, A., Drummond, M., Grimm, S. E., Grutters, J. P. C., Husereau, D., Koffijberg, H., Rothery, C., Wilson, E., & Heath, A. (2023) · Value in Health · doi:10.1016/j.jval.2023.06.014 · Cited by 40 · see citing works
Gruneau, L., Kechagias, S., Sandström, P., Ekstedt, M., & Henriksson, M. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000191 · Cited by 31 · see citing works
“The model was developed in R (version 4.2.1) and based on previous work on state cohort-transition models in R. [44] The model and data analysis were conducted in accordance with guidelines for cost-effectiveness modelling.”
MethodInfluentialHandels, R. L. H., Herring, W. L., Grimm, S. E., et al. (2024) · Value in Health · doi:10.1016/j.jval.2024.07.009 · Cited by 14 · see citing works
Packaging cost-effectiveness models in R: A tutorial.
Smith, R. A., Mohammed, W., & Schneider, P. P. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19656.1 · Cited by 14 · see citing works
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
Lazarus, J. V., Agirre‐Garrido, L., Díaz, L. A., Danpanichkul, P., Kivuyo, S. L., Kondili, L. A., Hagström, H., Takahashi, H., Pericàs, J. M., Spearman, C. W., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.42750 · Cited by 14 · see citing works
Mokri, H., Clephas, P. R. D., de Boer, R. A., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3213 · Cited by 11 · see citing works
Westwood, M. E., Ramaekers, B. L. T., Grimm, S. E., Armstrong, N., Wijnen, B. F. M., Ahmadu, C., de Kock, S., Noake, C., & Joore, M. A. (2024) · Health Technology Assessment · doi:10.3310/rdpa1487 · Cited by 18 · see citing works
Freitag, B., Uncovska, M., Meister, S., Prinz, C., & Fehring, L. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01324-0 · Cited by 6 · see citing works
Dickerson, J. C., Moen, M. T., Nielsen, P., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01960 · Cited by 6 · see citing works
Self-citationvan Alphen, A. M. I. A., van Hof, K. S., Gravesteijn, B. Y., Krijkamp, E., Bakx, P. A. G. M., Langenbach, P., Busschbach, J. J. V., Lingsma, H. F., de Jong, R. J. B., Value Based Operation Room Triage team collaborators, et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08854-x · Cited by 6 · see citing works
Self-citationAlarid-Escudero, F., Krijkamp, E., Enns, E. A., Yang, A., Hunink, M. G. M., Pechlivanoglou, P., & Jalal, H. (2023) · Medical Decision Making · doi:10.1177/0272989x221121747 · Cited by 5 · see citing works
“Please see the Supplementary Material and introductory cSTM tutorial for a detailed description of implementing discounting and within-cycle correction in R.(7)”
BackgroundMethodInfluentialSelf-citationAzizam, N. A., Hussain, M., Nauenberg, E., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307234 · Cited by 4 · see citing works
“The analyses were conducted using R software follows a conceptual algorithm for cost effectiveness model implementation in R developed Alarid-Escudero et al. [62].”
MethodDoan, T. T., Hutton, D. W., Wright, D. R., & Prosser, L. A. (2024) · Applied Health Economics and Health Policy · doi:10.1007/s40258-024-00872-6 · Cited by 4 · see citing works
“A common type of decision-analytic model is a cohort state-transition model (cSTM), which depicts the natural history of disease progression in a finite number of “health states” of a patient cohort [18, 19].”
Modeling Disability-Adjusted Life-Years for Policy and Decision Analysis
Leech, A. A., Zhu, J., Peterson, H., et al. (2025) · Medical Decision Making · doi:10.1177/0272989x251340077 · Cited by 2 · see citing works
Notenboom, M. L., Rhellab, R., Etnel, J. R. G., Huygens, S. A., Hjortnaes, J., Kluin, J., Takkenberg, J. J. M., & Veen, K. M. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae087 · Cited by 2 · see citing works
Gunnarsson, K. U., Henriksson, M., & Bendtsen, M. (2024) · Journal of Medical Internet Research · doi:10.2196/44574 · Cited by 3 · see citing works
“Other literature can be followed to model long-term health economic outcomes, which guides the construction, analysis, and implementation of health economic models [30,31].”
Bilancia, M., Solimando, A. G., Manca, F., Vacca, A., & Ria, R. (2025) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2025.108130 · Cited by 1 · see citing works
A Multistate Markovian Model of the Economic Burden for Allergy Immunotherapy
Bilancia, M., & Serviddio, G. (2025) · Applied Stochastic Models in Business and Industry · doi:10.1002/asmb.70017 · Cited by 1 · see citing works
Li, Z., Knowlton, G. S., Wheatley, M. M., Jenness, S. M., & Enns, E. A. (2025) · Medical Decision Making · doi:10.1177/0272989x251352210 · Cited by 1 · see citing works
“20,21 The 4 states of the Sick-Sicker model are Healthy (H), Sick (S1), Sicker (S2), and Dead (D).”
Self-citationModeling in R: a practical application using a cost-effectiveness analysis
Kouame, J. M., Siani, C., Kouakou, C. R. C., Gnanou, S., LaRue, S., & Guertin, J. R. (2025) · Health Economics Review · doi:10.1186/s13561-025-00686-9 · Cited by 1 · see citing works
Wiethoff, I., Witlox, W. J. A., Evers, S., et al. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01564-2 · Cited by 1 · see citing works
“The Markov model was built in R version 4.4.0 by using the Decision Analysis in R for Technologies in Health (DARTH) open-source coding template [35].”
InfluentialCost-effectiveness of multimodal intervention for the prevention of dementia in Japan
Takashi, N., Ohtera, S., Kuroda, Y., Arai, H., & Sakurai, T. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100460 · Cited by 1 · see citing works
“Probabilistic sensitivity analysis was conducted to simultaneously account for multiple uncertainties and evaluate the robustness of the base case results [22 – 24].”
Developing and Calibrating a Colorectal Cancer Microsimulation Model for Northern Ireland
Adair, O., McFerran, E., Lawler, M., van Duuren, L. A., & Lamrock, F. (2026) · PharmacoEconomics · doi:10.1007/s40273-025-01572-2 · Cited by 1 · see citing works
A Tutorial on Discrete Event Simulation Models Using a Cost-Effectiveness Analysis Example in R
Lopez-Mendez, M., Goldhaber‐Fiebert, J. D., & Alarid‐Escudero, F. (2026) · Medical Decision Making · doi:10.1177/0272989x261437826 · Cited by 1 · see citing works
“11,12 This compatibility allows use of validated functions for sampling parameter sets and outcome calculations.”
Self-citationYang, S., Wang, J., Miao, P., Zhang, C., Huang, J., Yuan, X., Zhang, Y., Dou, X., Zhang, Z., Liu, Z., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1801371 · Cited by 1 · see citing works
“Utility values for each health state, derived from previous EQ-5D studies, were held constant within each Markov cycle (28, 36).”
A 10-Year Cost-Effectiveness Analysis of Metabolic and Bariatric Surgery in Adolescents
Rode, J. B., Lim, F., Jenkins, T. M., Ryder, J. R., Inge, T. H., Hur, C., Helmrath, M. A., Courcoulas, A. P., Michalsky, M. P., Sisley, S. R., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.18648 · Cited by 1 · see citing works
Adair, O., Lamrock, F., O’Mahony, J. F., Lawler, M., & McFerran, E. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.007 · Cited by 3 · see citing works
A Tutorial on Discrete Event Simulation Models in R using a Cost-Effectiveness Analysis ExamplePreprint
Lopez-Mendez, M., Goldhaber‐Fiebert, J. D., & Alarid‐Escudero, F. (2025) · medRxiv · doi:10.1101/2025.05.15.25327635
“We demonstrate the implementation of the DES framework in R by simulating the time-dependent 4-state Sick-Sicker model (Enns et al., 2015) described in previous tutorials (Alarid-Escudero et al., 2023a, 2023b; Krijkamp et al., 2018).”
InfluentialSelf-citationSaing, S., Hannink, G., Geuzinge, H. A., et al. (2025) · Value in Health · doi:10.1016/j.jval.2025.05.004
Kang, D., Lim, J., Kim, L., et al. (2025) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-025-00679-9
“Agreement between predicted and observed survival was assessed both visually, via graphical overlay, and quantitatively, through calculation of the root mean squared error (RMSE) [27, 28].”
Preventing invasive aspergillosis in lung transplant recipients: A cost-utility analysis
Bitterman, R., Glembocki, A. I., Walti, L. N., Husain, S., & Pechlivanoglou, P. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.12.030
Self-citationGracia, V., Goldhaber‐Fiebert, J. D., & Alarid‐Escudero, F. (2026) · medRxiv · doi:10.64898/2026.02.27.26346591
“We focus on the Sick-Sicker cSTM, which includes four health states: Healthy, Sick, Sicker, and Dead [15, 16].”
Self-citationA Modern Approach for Constructing Decision Analytic Models in Microsoft Excel
Paulden, M. (2026) · PharmacoEconomics · doi:10.1007/s40273-025-01582-0
Rhellab, R., Notenboom, M. L., Etnel, J. R. G., Kluin, J., Steyerberg, E. W., Takkenberg, J. J. M., & Veen, K. M. (2026) · BMC Medical Research Methodology · doi:10.1186/s12874-026-02910-4
“This would amount to a probabilistic sensitivity analysis (PSA), of which tutorials have been previously published [9].”
Solimando, A. G., Desantis, V., Marzo, L. D., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1774263
“This study employed a state-transition Markov model to evaluate the cost-effectiveness offour treatment regimens for elderly patients with multiple myeloma (MM) (13, 14).”
Early economic evaluation of tissue engineered vascular access grafts for hemodialysis
de Groot, H., Besseling, P. J., van Lieshout, C., et al. (2026) · Regenerative Medicine · doi:10.1080/17460751.2026.2726833
Distributional Cost-Effectiveness Analysis Using Microsimulation in R: A Tutorial
Barry, L. E., & Nianogo, R. A. (2026) · Medical Decision Making · doi:10.1177/0272989x261485229
Saini, J., Tieu, P., Lozano, C. S., et al. (2026) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2026.10705
- Authors
- Alarid-Escudero, F., Krijkamp, E., Enns, E. A., Yang, A., Hunink, M. G. M., Pechlivanoglou, P., & Jalal, H.
- Affiliations
- Division of Public Administration, Center for Research and Teaching in Economics (CIDE), Aguascalientes, Aguascalientes, Mexico
- Erasmus MC (NL)
- University of Minnesota (US)
- Hospital for Sick Children (CA)
- Harvard University (US)
- University of Toronto (CA)
- University of Ottawa (CA)
- ORCID
- Venue
- Medical Decision Making
- Publisher
- SAGE Publications
- Published
- 2022-06-30
- Volume
- 43
- Issue
- 1
- Pages
- 3-20
- ISSN
- 0272-989X (ISSN-L)
- 1552-681X
- PMC
- PMC9742144
- OpenAlex
- W3195294569
- Cited by
- 39
- References
- 45
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 8 · 2023: 3 · 2022: 2 · 2021: 1
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Medical Decision Making (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- arXiv (Cornell University) (submittedVersion)
- PubMed Central (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- arXiv (Cornell University)
- Funders
- National Institutes of Health (5u01ca253913-05)
- National Institute on Drug Abuse (K01DA048985)
- National Cancer Institute (U01-CA253913, U01CA199335, U01CA265750)
- National Institute of Allergy and Infectious Diseases (K25AI118476)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Management Science and Operations Research › Simulation Techniques and Applications
- Keywords
- decision models, cost-effectiveness analysis, health state transitions, probabilistic sensitivity analysis, R implementation
- MeSH terms
- Cost-Effectiveness Analysis, Cost-Benefit Analysis, Humans, Markov Chains, Probability, Programming Languages, Software, Quality-Adjusted Life Years
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-16.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-16.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review